. Author manuscript; available in PMC: 2010 Oct 1.

Published in final edited form as: Acta Pharmacol Sin. 2010 Mar 22;31(4):450–454. doi: 10.1038/aps.2010.25

Table 2.

Mixed effect model analysis of 24-week repaglinide treatment effect, genotypes effect and their interaction effect

Parameters	Repaglinide treatment effect (P value)	Genotypes effect (P value)	Genotypes and treatment interaction effect (P value)
BMI(kg/m²)	0.039	0.064	0.198
Waist–hip ratio	0.907	0.804	0.527
Glycated hemoglobin (%)	<0.001	0.427	0.585
Fasting plasma glucose (mmol/L)	<0.001	0.631	0.573
2-h Plasma glucose (mmol/L)	<0.001	0.494	0.328
HOMA-IR	0.056	0.824	0.013
HOMA-B	<0.001	0.881	0.806
Fasting insulin (pmol/L)	<0.001	0.812	0.103
Acute insulin secretion(pmol/L)	0.270	0.875	0.395
Acute insulin secretion (pmol/L)/Plasma glucose (mmol/L)	0.769	0.032	0.738